Nine case-control studies involving 3540 cases and 3953 controls were included in the meta-analysis, which revealed that the XPGrs751402 polymorphism is positively associated with GC risk and could be viewed as a risk factor of GC in three genetic models.
Odds ratio (OR) and 95% confidence interval (CI) were used to assess the association between XPG polymorphisms (rs751402, rs873601, and rs2296147) and cancer risk.